Home / prostate

prostate

Real-world results confirm benefit of PSMA therapy for prostate cancer

Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy is safe and effective for patients with metastatic castration-resistant prostate cancer (mCRPC) in routine clinical practice, consistent with outcomes from the landmark VISION trial. An analysis of outcomes from a French early-access program, the largest real-world cohort of patients studied to date, confirms the benefit-risk profile of the therapy, […]

PSMA PETCT-targeted biopsy improves detection of clinically significant prostate cancer

PSMA PETCT-targeted biopsy detects more clinically significant prostate cancer than systematic biopsy alone in men whose MRI findings are negative or inconclusive yet have persistent clinical risk factors. According to new research published in the September issue of The Journal of Nuclear Medicine, combining the two biopsy approaches is even more effective, nearly doubling the […]

Some prostate cancers could be diagnosed from MRI alone

New research from UCL and UCLH suggests that prostate cancer in some men can be identified from an MRI scan with a very high degree of confidence, potentially reducing the need for a biopsy. Four experienced radiologists, working both individually and as a group, identified a subset of patients in whom they were ‘99 per […]

Study shows AI can be safely deployed in NHS prostate cancer diagnosis

Findings from the landmark Articulate Pro study have now been published, marking a major milestone for the use of artificial intelligence (AI) in NHS histopathology laboratories and demonstrating its potential to improve and standardise prostate cancer diagnosis. Led by Professor Clare Verrill at the University of Oxford’s Nuffield Department of Surgical Sciences, the study is one of the first examples […]

DNA blood test improves patient selection for radiopharmaceutical therapy in prostate cancer

A noninvasive DNA blood test can identify metastatic castration-resistant prostate cancer (mCRPC) patients who are most likely to benefit from 223Ra radiopharmaceutical therapy and monitor their progress throughout treatment, according to new research published in the July issue of The Journal of Nuclear Medicine. Incorporating this new approach to DNA profiling into clinical practice has the potential […]